Enabling Growing Genomic Applications in Chinese Clinical Market
Designed specifically for the clinical laboratory environment, the MiSeqDx Sequencing System is a benchtop sequencer that incorporates an easy-to-use workflow and data output tailored to the diverse needs of clinical labs. Taking advantage of proven
“The clearance of the MiSeqDx in
The MiSeqDx Sequencing System now has regulatory approval in
For more information on the MiSeqDx Sequencing System, please visit www.illumina.com/miseqdx.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Use of forward-looking statements
This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables, including our diagnostic kit products, and to deploy new products such as the MiSeq™Dx System, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180827005500/en/
Source:
Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-255-5243
IR@illumina.com
or
Media:
Melinda Hutcheon
858-882-6822
PR@illumina.com